The Wolverine blend is BPC-157 and TB-500 in one vial, and it's the most popular repair stack in this market. It also has a problem nobody selling it mentions. Run separately, these two compounds are dosed on completely different rhythms: BPC-157 daily, TB-500 in weekly loading doses. Put them in one vial and you have to pick one schedule for both, and whichever you pick is wrong for one of them.
Vial size isn't part of what follows, since the amount of bacteriostatic water you add sets your concentration either way. Our reconstitution calculator handles that math for whatever vial and target amount you're working with.
What it is
Two compounds, sold together because they're the two things people reach for when something is torn, strained or refusing to heal.
BPC-157 is a fifteen-amino-acid fragment derived from a protein found in stomach fluid. The research on it is broad and almost entirely in rodents: tendon, ligament, gut, and a consistent thread about new blood vessel growth into damaged tissue.
TB-500 is a synthetic piece of thymosin beta-4, a protein involved in how cells move and reorganise during healing. Its research thread is about cell migration into a wound and about the structural protein scaffolding that has to reassemble for tissue to knit.
The case for combining them is that they work on different parts of the same process. One improves the blood supply to an injury, the other helps cells get there and rebuild. It's a coherent argument, and like most stack rationales on this site it has never been tested as a combination in anything.
What people use it for
Injuries that aren't healing on schedule. Tendons and ligaments most of all, because those heal slowly and badly in the best of circumstances and considerably worse from forty onwards. Shoulders, knees, elbows, Achilles, the plantar fascia.
The second use is the accumulation rather than the injury: the general midlife sense that recovery takes longer than it used to, and that things which used to resolve on their own now hang around for months.
Gut is a third thread and belongs mostly to the BPC-157 half. If gut is your actual target, the TB-500 in the blend is doing very little for you and you may be paying for it unnecessarily.
Formulations
Sold as premixed lyophilized powder. Across the vendors we track, 10 mg vials dominate, with 5 mg and 20 mg both common and a tail of larger sizes.
The same labelling problem the other blends have applies here. A vial described as "10 mg" may hold 5 mg of each compound or 10 mg of each, and vendors use both conventions without saying which. That makes per-milligram comparison across blend listings unreliable, and it's worth asking before buying rather than assuming. Read the product name for a per-compound breakdown; where there's only one number, ask.
Dosing protocols
No approved product exists for either compound, so everything here is convention. The separate-vial figures are listed first because they're what the blend is trying to approximate.
See the Wolverine blend research notes for the underlying research on each component.
| Pattern | Amount | How often | Where it comes from |
|---|---|---|---|
| Separate vials, BPC-157 half | 250–500 mcg | Once or twice daily | The circulating convention, with no named source. Daily dosing is the consistent part. |
| Separate vials, TB-500 half | 2–5 mg | Twice weekly while loading, then weekly | A loading-then-maintenance shape, taken from an equine product insert rather than from any human work. Note the frequency: weekly, against BPC-157's daily. |
| Premixed blend, as it actually runs | Whatever one draw gives you | Once daily, most commonly | Daily is the usual compromise, because it suits the BPC-157 half. That means the TB-500 half is being given seven times a week instead of once or twice. |
| What research established | Nothing, for the pairing | — | Each compound's own research is in animals. The combination has never been tested in anything, at any ratio, on any schedule. BPC-157's single published human study used an amount roughly 600 times smaller than the community figure. |
All patterns above are subcutaneous injection.
The schedule clash, which is the real problem with this blend
Work through what daily dosing of a premixed vial actually does. The BPC-157 gets what it conventionally gets. The TB-500 gets given every day, when its own convention is once or twice a week. Over a week that's five to seven times more TB-500 than the separate-vial protocol describes.
You can dose the blend weekly instead, to suit the TB-500. Then the BPC-157 is given once a week when its convention is daily, which is a sixth of what it would otherwise get.
There is no third option. Two compounds in one solution get one schedule, and these two don't want the same one. Nobody has studied whether it matters, so we can't tell you it's harmful or that it wastes your money. What we can tell you is that the premixed blend cannot reproduce the two protocols it's marketed as combining, and that the vendors selling it never raise this.
Amount total, for planning your purchase. On a blend holding 5 mg of each compound, dosed daily to suit the BPC-157 half, a 10 mg total vial covers roughly ten to twenty days depending on your draw. An eight-week run is therefore three to five vials. Compare vendors against that, and against the labelling ambiguity above.
How much to reconstitute at once. A reconstituted vial keeps about 28 days refrigerated, which daily dosing comfortably fits inside on a 10 mg vial. On a 20 mg vial at a lower daily draw it may not, so mix what a month uses rather than the whole thing. Working example: a blend vial holding 5 mg of each compound is 10 mg total; into 2 mL of bacteriostatic water that gives 5,000 mcg per mL of combined material, or 2,500 mcg per mL of each. A 10-unit draw is 0.1 mL, delivering 500 mcg total: 250 mcg of each. See how much to reconstitute at once for the general math.
Cycling guidelines
Four to eight weeks is the pattern described most often, tied to an injury healing rather than to a calendar. Longer runs come up for chronic problems. Nothing is established for either.
The sensible framing is that this is a repair protocol rather than a maintenance one. If it's working you should eventually not need it, and if twelve weeks have passed with no change in a specific injury, that's information.
Signs a course is commonly stopped or reconsidered:
- Injection site reactions that don't settle, more likely on a daily schedule
- Any new swelling or discomfort in the injured area rather than less
- Light-headedness or flushing after a dose
- Eight to twelve weeks with no change in the thing you're treating
Stacking
This is already a stack, so the question is what gets added.
KPV is the most sensible addition, and it's the logic behind the GLOW and KLOW blends: it calms inflammation where these two rebuild tissue. Different job, no overlap.
GHK-Cu comes up where skin is part of the picture, which is what turns this blend into GLOW.
Combinations to approach carefully: nothing specific is flagged. The general caution worth stating is that stacking more compounds onto an untested combination compounds the not-knowing rather than dividing it.
Expected results timeline
First two weeks: generally nothing. Tissue repair is slow and neither compound has an acute effect people reliably notice.
Four to eight weeks: this is where reports cluster, described as an injury that had stopped improving starting to improve again. All self-reported.
Beyond: no data at all, in humans, for either compound at these amounts.
What to expect realistically: the animal research on both compounds is genuinely interesting, fairly consistent, and entirely in animals. BPC-157's one human study used an amount hundreds of times below what people run, which tells you how little the human dosing rests on. This is a well-liked stack with a plausible mechanism and effectively no human evidence, and the honest reason it's popular is that tendon injuries are miserable and the alternatives are rest and time.
Administration technique
- The lyophilized powder is reconstituted with bacteriostatic water, at a concentration set by the reconstitution calculator. For a blend, run the calculation on the total material and remember the draw splits between the two compounds in whatever ratio the vial holds.
- The solution is swirled gently to dissolve rather than shaken.
- The vial is commonly labelled with the date and with whether the milligram figure is per compound or total, since that ambiguity follows the vial home.
- The calculated volume is drawn into an insulin syringe.
- A subcutaneous site is chosen, with sites rotated daily. Some people inject near the injury on the reasoning that local delivery helps; nothing establishes that, and BPC-157's animal work suggests the effect is systemic.
- The skin is pinched and the injection given at roughly a 45-degree angle.
- Timing is unconstrained: no meal or sleep dependency.
Side effects and safety
Common: injection site reactions, and little else. Both compounds are consistently described as well tolerated, which is community experience rather than surveillance.
Less common: light-headedness or flushing shortly after a dose, headache, and occasional reports of fatigue.
What we don't know: nearly everything, and more than usual because this is a combination. Neither compound has meaningful human safety data at these amounts, and the pairing has none at all. The most discussed theoretical concern is that both compounds encourage new blood vessel growth, which is exactly what a tumour also needs, so anyone with a cancer history should treat that as a real conversation rather than a footnote. Nothing establishes the risk; nothing rules it out.
Contraindications: active cancer, on the reasoning above. Pregnancy, breastfeeding and use in minors have no data.
Drug interactions: none established.
The blend vs. two separate vials
Given the schedule clash, this decision matters more here than on most blend pages.
| Premixed blend | Two separate vials | |
|---|---|---|
| Schedule | One schedule for both, which suits only one of them | BPC-157 daily and TB-500 weekly, as each convention describes |
| Ratio control | Fixed by the vendor | Yours |
| Injections | One | Daily plus a weekly extra |
| Price comparability | Poor, because of the labelling ambiguity | Good, each priced on its own terms |
| If your target is gut | You're buying TB-500 you don't need | Buy BPC-157 alone |
Choose the blend if: convenience is the deciding factor and you accept that one half is running off-schedule.
Choose separate vials if: you want each compound on the rhythm its own convention describes, or your target is really only one of them.
See the BPC-157 guide and the TB-500 guide for each on its own.
Storage and handling
Lyophilized powder: refrigerate at 2 to 8°C and protect from light; frozen for longer storage. Take lot-specific stability from the vendor's certificate of analysis.
Reconstituted solution: refrigerate and use within about 28 days. Two peptides share one solution here and there's no reason to assume they degrade at the same rate, so plan around the shorter of the two windows.
Signs of degradation:
- Cloudiness or visible particles in a solution that was previously clear
- Discoloration of the powder or the reconstituted liquid
- Powder that has clumped or gone sticky
FAQ
What's actually in it? BPC-157 and TB-500, in whatever ratio the vendor chose, which is usually equal parts.
Why does the schedule matter? BPC-157's convention is daily and TB-500's is weekly. One vial means one schedule, so one of them runs off its own pattern whichever you pick.
Blend or separate vials? Blend for convenience, separate for correct scheduling and honest price comparison.
Does "10 mg" mean 10 mg of each? Sometimes. Vendors use both conventions and rarely say which, so ask before comparing prices.
Should I inject near the injury? People do, and nothing establishes that it helps. The animal work suggests the effect is systemic.
Has the combination been studied? No. Neither compound has meaningful human data, and the pairing has none.
What if my problem is my gut? Then you want BPC-157 alone and the TB-500 is dead weight.
How long do people run it? Four to eight weeks, tied to an injury rather than a calendar.
Bottom line
Key dosing takeaways:
- Separately these are a daily compound and a weekly one; a premixed vial forces both onto one schedule that fits only one of them
- Blend vials are labelled inconsistently, so "10 mg" may mean 10 mg total or 10 mg of each
- The combination has never been studied in anything, and BPC-157's single human study used an amount hundreds of times smaller than what people run
Best practices:
- Asking what the milligrams refer to before comparing prices across blend vendors
- Buying separate vials if you care about each compound being on its own rhythm
- Buying BPC-157 alone if your target is the gut rather than a tendon
Works best for people who:
- Have a soft-tissue injury that has stopped improving on its own
- Want one injection rather than two and will accept the schedule compromise knowingly
- Can hold that the mechanism is plausible and the human evidence is close to nonexistent
Both compounds here are sold for research, and the combination has never been tested in anything. You already know that. You're an adult making an informed call about your own body, and that's yours to make.